FIELD: medicine.
SUBSTANCE: amplification of V2M HV2 and CFLAR genetic loci fragments is performed using polymerase chain reaction in real time using a set of high-affinity primers on a selected DNA matrix, quantitative interpretation of amplification results and calculation of relative genes authenticity by the formula rC=2-(Ct(gene target)-Ct(B2M)) is performed, where rC is relative gene abundance in the tumor tissue, Ct is the average value of fluorescence signals, the relative gene abundance values obtained are compared to predicted ones, and at rCHV2<870 and rCCFLAR>0.40 absence of metastases is predicted, and at rCHV2>870 and RCCFLAR<0.40, metastases development is predicted.
EFFECT: method allows to make an early prediction for the development of metastases in patients with gastric cancer.
2 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
TEST SYSTEM “HV2 mtDNA-PCR” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH GASTRIC CANCER | 2017 |
|
RU2683571C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF GASTRIC CANCER OF DIFFERENT HISTOLOGICAL TYPES | 2015 |
|
RU2613139C1 |
METHOD FOR PREDICTING THE DEVELOPMENT OF METASTASES IN REGIONAL LYMPH NODES IN PATIENTS WITH GASTRIC ADENOCARCINOMA | 2017 |
|
RU2661600C1 |
MINIMALLY INVASIVE METHOD FOR DIAGNOSTICS OF LUNG CANCER ON BASIS OF CHANGING COPY NUMBER OF MTDNA HV2 LOCUS | 2018 |
|
RU2678227C1 |
MINIMALLY INVASIVE METHOD FOR DETECTING SENSITIVITY OF RECTAL TUMOUR TO RADIATION THERAPY BASED ON CHANGE IN ABUNDANCE OF N2AX AND RBBP8 GENES | 2019 |
|
RU2740576C1 |
MINIMALLY INVASIVE METHOD FOR DIAGNOSING METASTATIC LESIONS OF REGIONAL LYMPH NODES IN PATIENTS WITH CERVICAL CANCER BASED ON THE COPY NUMBER OF THE CCND1 AND PPARGC1A GENES | 2021 |
|
RU2766774C1 |
METHOD FOR PREDICTION OF PERITONEAL METASTASES OF GASTRIC CANCER | 2018 |
|
RU2686689C1 |
ESSC-TIPE-1TEST-SYSTEM FOR MOLECULAR-GENETIC TYPING OF SQUAMOUS OESOPHAGEAL CANCER | 2020 |
|
RU2742468C1 |
METHOD OF PREDICTING METASTASIS OF STOMACH CANCER TUMORS | 2021 |
|
RU2806432C2 |
METHOD FOR PREDICTION OF DEVELOPING METASTASES IN UTERINE CANCER PATIENTS BASED ON ANALYSIS OF MAGEA1, MAGEB2 AND PRAME1 GENE EXPRESSION | 2018 |
|
RU2698895C1 |
Authors
Dates
2017-07-04—Published
2016-06-03—Filed